Abbott Laboratories (NYSE: ABT) open the trading on Thursday, with a bit cautious approach as it glided -1.18% to $123.53, before settling in for the price of $125.0 at the close. Taking a more long-term approach, ABT posted a 52-week range of $110.86-$141.23.
It was noted that the giant of the Healthcare sector posted annual sales growth of 29.98% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 29.98%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 10.31%. This publicly-traded company’s shares outstanding now amounts to $1.74 billion, simultaneously with a float of $1.73 billion. The organization now has a market capitalization sitting at $214.80 billion.
Abbott Laboratories (ABT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Devices industry. Abbott Laboratories’s current insider ownership accounts for 0.67%, in contrast to 80.59% institutional ownership. According to the most recent insider trade that took place on Nov 25 ’25, this organization’s Senior Vice President sold 1,586 shares at the rate of 128.02, making the entire transaction reach 203,043 in total value, affecting insider ownership by 30,384.
Abbott Laboratories (ABT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.2 per share during the current fiscal year.
Abbott Laboratories’s EPS increase for this current 12-month fiscal period is 10.31% and is forecasted to reach 5.67 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 10.30% through the next 5 years, which can be compared against the 29.98% growth it accomplished over the previous five years trading on the market.
Abbott Laboratories (NYSE: ABT) Trading Performance Indicators
Let’s observe the current performance indicators for Abbott Laboratories (ABT). It’s Quick Ratio in the last reported quarter now stands at 1.24. Alongside those numbers, its PE Ratio stands at $15.49, and its Beta score is 0.75. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.90. Similarly, its price to free cash flow for trailing twelve months is now 31.05.
In the same vein, ABT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 7.97, a figure that is expected to reach 1.50 in the next quarter, and analysts are predicting that it will be 5.67 at the market close of one year from today.
